Parkinson's disease plasma biomarkers: An automated literature analysis followed by experimental validation

Journal of Proteomics

Volumn 90, Issue , 2013, Pages 107-114

  Alberio, Tiziana ^a   Bucci, Enrico M ^b   Natale, Massimo ^b,c   Bonino, Dario ^b   Di Giovanni, Marco ^d   Bottacchi, Edo ^d   Fasano, Mauro ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b BioDigitalValley Srl   (Italy)

^c POLITECNICO DI TORINO   (Italy)

^d Aosta Hospital   (Italy)

Author keywords

2 DE; Biomarkers; Meta analysis; Parkinson's disease; Plasma

Indexed keywords

ALPHA 1 MICROGLOBULIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; FIBRINOGEN; FIBRINOGEN BETA; HAPTOGLOBIN; HAPTOGLOBIN ALPHA; HAPTOGLOBIN BETA; HEMOPEXIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN MU CHAIN; IMMUNOGLOBULIN MU CHAIN C REGION; PREALBUMIN; PROTEIN; SERUM ALBUMIN; SERUM AMYLOID P; TETRANECTIN; THROMBIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PLASMA PROTEIN;

AGED; ALBUMIN BLOOD LEVEL; AMINO ACID SEQUENCE; ARTICLE; AUTOMATION; BIOINFORMATICS; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TWO DIMENSIONAL ELECTROPHORESIS; VALIDATION PROCESS; BLOOD; CLINICAL TRIAL; DATA MINING; INFORMATION PROCESSING; METABOLISM; MIDDLE AGED;

AGED; AUTOMATIC DATA PROCESSING; BIOLOGICAL MARKERS; BLOOD PROTEINS; DATA MINING; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84882594262     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.01.025     Document Type: Article

References (31)

1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79:368-376.
2. Shulman J.M., De Jager P.L., Feany M.B. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011, 6:193-222.
3. Morgan J.C., Mehta S.H., Sethi K.D. Biomarkers in Parkinson's disease. Curr Neurol Neurosci Rep 2010, 10:423-430.
4. Alberio T., Fasano M. Proteomics in Parkinson's disease: an unbiased approach towards peripheral biomarkers and new therapies. J Biotechnol 2011, 156:325-337.
5. Gerlach M., Maetzler W., Broich K., Hampel H., Rems L., Reum T., et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 2012, 119:39-52.
6. Frasier M., Chowdhury S., Eberling J., Sherer T. Biomarkers in Parkinson's disease: a funder's perspective. Biomark Med 2010, 4:723-729.
7. Sheta E.A., Appel S.H., Goldknopf I.L. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev Proteomics 2006, 3:45-62.
8. Jacob A.M., Turck C.W. Detection of post-translational modifications by fluorescent staining of two-dimensional gels. Methods Mol Biol 2008, 446:21-32.
9. Jacobs J.M., Adkins J.N., Qian W.J., Liu T., Shen Y., Camp D.G., et al. Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res 2005, 4:1073-1085.
10. Surinova S., Schiess R., Hüttenhain R., Cerciello F., Wollscheid B., Aebersold R. On the development of plasma protein biomarkers. J Proteome Res 2011, 10:5-16.
11. Rosenberg L.H., Franzén B., Auer G., Lehtiö J., Forshed J. Multivariate meta-analysis of proteomics data from human prostate and colon tumours. BMC Bioinforma 2010, 11:468.
12. Natale M., Bonino D., Consoli P., Alberio T., Ravid R.G., Fasano M., et al. A meta-analysis of two-dimensional electrophoresis pattern of the Parkinson's disease-related protein DJ-1. Bioinformatics 2010, 26:946-952.
13. Ioannidis J.P.A., Khoury M.J. Improving validation practices in "Omics" research. Science 2011, 334:1230-1232.
14. Griss J., Haudek-Prinz V., Gerner C. GPDE: a biological proteomic database for biomarker discovery and evaluation. Proteomics 2011, 11:1000-1004.
15. Albrecht D., Kniemeyer O., Brakhage A.A., Guthke R. Missing values in gel-based proteomics. Proteomics 2010, 10:1202-1211.
16. McDonald J.H. Handbook of biological statistics 2009, Sparky House Publishing, Baltimore. 2nd ed.
17. Alberio T., Pippione A.C., Comi C., Olgiati S., Cecconi D., Zibetti M., et al. Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease. IUBMB Life 2012, 64:846-852.
18. R Development Core Team R: A language and environment for statistical computing 2009, R Foundation for Statistical Computing, Vienna.
19. Alberio T., Bossi A.M., Milli A., Parma E., Gariboldi M.B., Tosi G., et al. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis. FEBS J 2010, 277:4909-4919.
20. Tansey M.G., McCoy M.K., Frank-Cannon T.C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007, 208:1-25.
21. Argüelles S., Venero J.L., García-Rodriguez S., Tomas-Camardiel M., Ayala A., Cano J., et al. Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson's disease. Neurochem Int 2010, 57:227-234.
22. Goldknopf I.L., Bryson J.K., Strelets I., Quintero S., Sheta E.A., Mosqueda M., et al. Abnormal serum concentrations of proteins in Parkinson's disease. Biochem Biophys Res Commun 2009, 389:321-327.
23. Galicia G., Maes W., Verbinnen B., Kasran A., Bullens D., Arredouani M., et al. Haptoglobin deficiency facilitates the development of autoimmune inflammation. Eur J Immunol 2009, 39:3404-3412.
24. Costa-Mallen P., Checkoway H., Zabeti A., Edenfield M.J., Swanson P.D., Longstreth W.T., et al. The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:216-222.
25. Finehout E.J., Franck Z., Lee K.H. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 2005, 21:93-101.
26. Cannon J.R., Hua Y., Richardson R.J., Xi G., Keep R.F., Schallert T. The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing. Behav Brain Res 2007, 183:161-168.
27. Sokolova E., Reiser G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost 2008, 100:576-581.
28. Riek-Burchardt M., Striggow F., Henrich-Noack P., Reiser G., Reymann K.G. Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. Neurosci Lett 2002, 329:181-184.
29. Hu Y.Q., Liu B.J., Dluzen D.E., Koo P.H. Alteration of dopamine release by rat caudate putamen tissues superfused with alpha 2-macroglobulin. J Neurosci Res 1996, 43:71-77.
30. Nicoletti G., Annesi G., Tomaino C., Spadafora P., Pasqua A.A., Annesi F., et al. No evidence of association between the alpha-2 macroglobulin gene and Parkinson's disease in a case-control sample. Neurosci Lett 2002, 328(1):65-67.
31. Dufek M., Hamanová M., Lokaj J., Goldemund D., Rektorová I., Michálková Z., et al. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:318-320.